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ABSTRACT
Hypersexual disorder (HD) was proposed as a diagnosis in the DSM-5 and the classification
‘Compulsive Sexual Behavior Disorder’ is now presented as an impulse-control disorder in ICD-11.
HD incorporates several pathophysiological mechanisms; including impulsivity, compulsivity, sexual
desire dysregulation and sexual addiction. No previous study investigated HD in a methylation
analysis limited to microRNA (miRNA) associated CpG-sites. The genome wide methylation pattern
was measured in whole blood from 60 subjects with HD and 33 healthy volunteers using the Illumina
EPIC BeadChip. 8,852 miRNA associated CpG-sites were investigated in multiple linear regression
analyses of methylation M-values to a binary independent variable of disease state (HD or healthy
volunteer), adjusting for optimally determined covariates. Expression levels of candidatemiRNAs were
investigated in the same individuals for differential expression analysis. Candidate methylation loci
were further studied for an association with alcohol dependence in an independent cohort of 107
subjects. Two CpG-sites were borderline significant in HD – cg18222192 (MIR708)(p < 10E-05,
pFDR = 5.81E-02) and cg01299774 (MIR4456)(p < 10E-06, pFDR = 5.81E-02). MIR4456 was significantly
lower expressed in HD in both univariate (p < 0.0001) and multivariate (p < 0.05) analyses.
Cg01299774 methylation levels were inversely correlated with expression levels of MIR4456 (p <
0.01) and were also differentially methylated in alcohol dependence (p = 0.026). Gene target predic-
tion and pathway analysis revealed that MIR4456 putatively targets genes preferentially expressed in
brain and that are involved in major neuronal molecular mechanisms thought to be relevant for HD,
e.g., the oxytocin signalling pathway. In summary, our study implicates a potential contribution of
MIR4456 in the pathophysiology of HD by putatively influencing oxytocin signalling.
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Introduction
Hypersexual disorder (HD) was conceptualized as
a non-paraphilic sexual behaviour disorder with
impulsivity content and proposed as a diagnosis for
inclusion in the DSM-5 [1]. The classification
‘Compulsive Sexual Behavior Disorder’ is now pre-
sented as an impulse-control disorder in ICD-11 [2].
HD incorporates different pathophysiological
mechanisms including impulsivity, compulsivity, sex-
ual desire dysregulation and sexual addiction. Today,
little is known about the neurobiology behind this
disorder. Focusing on neuroendocrine systems,
hyperactive HPA axis assessed with the dexametha-
sone test [3]was found in men with hypersexual dis-
order and a recent study by Jokinen et al. examined
methylation of hypothalamic-pituitary-adrenal
(HPA) axis related genes in hypersexual disorder
and discovered epigenetic changes in the CRH gene,
an important integrator of neuroendocrine stress
responses in the brain, with a key role in the addiction
processes [4]. Drawing on the cumulative evidence
from different scientific perspectives such as neuroi-
maging studies, neuropharmacological evidence,
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genetic as well as animal studies, Kühn et al. suggested
that HD is associated with alterations in the dopami-
nergic system and specific regions of the brain, includ-
ing the frontal lobe, amygdala, hippocampus,
hypothalamus, septum and regions of the brain that
process reward [5]. An increasing number of studies
suggest a [5] significant role of epigenetic modifica-
tions, such as DNA methylation and histone acetyla-
tion, on sexual behaviour and human brain
functioning [6–8]. Variations in DNA methylation
modify gene expression by modulating the transcrip-
tional expression or by recruiting specific proteins
that remodel the chromatin state. Furthermore,
methylation levels have been shown to influence the
expression of fine-regulatory genes such as
microRNAs (miRNAs) [9,10]. A further understand-
ing of the interaction between DNA methylation,
miRNA activity and HD may lead to new insights
into the pathogenesis of this disorder that could con-
tribute to novel treatment options to improve the
clinical outcome of those affected.
Growing evidence suggests a role of DNA
methylation in the pathophysiology of several psy-
chiatric diseases, including major depressive dis-
order [11], bipolar disorder [12], psychosis [13]
and post-traumatic stress disorder [14]. In support
of this, shifts in epigenetic patterns have been
shown to influence several aspects of CNS func-
tions [15,16]. In the genome, DNA methylation
refers to the addition of a methyl group to the 5ʹ-
position of the cytosine pyrimidine ring. The
extent of methylation can influence transcriptional
activity by modulating the binding of transcription
factors to the DNA, resulting in altered transcrip-
tion of adjacent genes, or by altering chromatin
states, affecting transcriptional activity of a larger
cluster of genes. In animal models, epigenetic
modifications have been shown to significantly
affect sexual behaviour. A review by Matsuda
et al. summarized literature that, among others,
provided evidence that histone modifications and
DNA methylation changes in the estrogen receptor
α (ERα) can influence sociosexual behaviour [6].
Wang et al. showed that the formation of partner
preference was improved by histone deacetylase-
inhibitors in female prairie voles, an effect which
was mediated by an epigenetically driven up-
regulation of oxytocin receptor and vasopressin
V1a receptor expression in the nucleus accumbens
[7]. Zeh et al. further suggested that epigenetic
variation could contribute to explaining post-
copulatory sexual selection and linking sperm
competitive ability to offspring fitness [8].
Recent studies have revealed altered miRNA
expression profiles in the circulation and brain of
patients with psychiatric disorders [17,18]. Drawing
on this evidence, Issler et al. suggested that miRNAs
targeting mRNAs expressed in brain could become
novel treatment options in psychiatric disorders [19].
miRNAs are small non-coding RNA molecules of
approximately 22 nucleotides in length. By inhibiting
or degrading target mRNAmolecules, miRNA are an
efficient mode of post-transcriptional regulation
which modulates the protein expression of more
than 50% of the known protein-coding genes [20].
Certain miRNAs are capable of silencing or modulat-
ing expression levels of up to several hundred differ-
ent genes [19]. Furthermore, these miRNAs are
remarkably stable in body fluids [21] and exosomes
export miRNAs outside of the cell into the circulation
and can cross the blood-brain barrier [22]. As such,
they represent a biological model whereby peripheral
processes can potentially modulate the expression of
mRNAs and proteins in brain, involved the pathogen-
esis of mental disorders and may act as biomar-
kers [23].
HD has not previously been investigated with
regards to epigenomics and transcriptomics in
a methylome-wide study approach. In this study, we
perform a DNA methylation analysis of miRNA-
associated CpG-sites in peripheral blood in order to
examine if any DNA methylation patterns are asso-
ciated with HD compared to healthy volunteers. As
a second step, wemeasured the expressional profile of
identified candidate miRNA to investigate whether
they were differentially expressed in HD. As a third
step, we investigated whether themethylation levels of
candidate CpG-sites contributes to explaining the dif-
ferential expression pattern of the associated miRNAs
in HD. Associations of methylation and transcription
were further validated in an independent cohort of 26
healthy volunteers. CpG sites that were differentially
methylated by disease state (hypersexual disorder or
healthy control) were further investigated for an asso-
ciation with alcohol dependence in an independent
cohort of 107 subjects. An alcohol dependence cohort
was chosen as validation data set mainly due to data
availability reasons but also as this phenotype is
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believed to share common features with primarily the
addictive component of HD.
Methods
Characterization of the discovery group
Ethics and patient consent
The study protocols were approved by the
Regional Ethical Review Board in Stockholm
(Dnrs: 2013/1335–31/2) and all participants gave
their written informed consent to participate in
the study. The study was performed in accordance
with relevant guidelines and regulations.
HD patients
Details on the HD cohort have been previously pub-
lished [3,4]. The study was performed at the Centre
for Andrology and Sexual Medicine (CASM) at the
Karolinska University Hospital, a multidisciplinary
centre for diagnostics and treatment of patients with
sexual dysfunctions. Seventy-four patients seeking
medical and/or psychotherapeutic treatment were
recruited in the study of neuroendocrine and epige-
netic markers of HD. Inclusion criteria were
a diagnosis of HD defined according to the DSM-5
proposed criteria for HD by Kafka et al. [1], age of 18
years or older and available contact information.
Patients were excluded if they had any current psy-
chotic illness, other psychiatric disease requiring
immediate treatment, current alcohol or drug abuse
and serious physical illness such as severe hepatic or
renal disease. Subsequently, all patients were evalu-
ated in a face to face interview by a trained psychiatrist
and a psychologist using the Mini International
Neuropsychiatric Interview (MINI) protocol [24] to
establish psychiatric diagnoses.
Healthy volunteers
Healthy volunteers were recruited from the
Karolinska Trial Alliance (KTA) database and as pre-
viously published [4]. Healthy volunteers were chosen
to match HD patients by age and equal blood collec-
tion times in fall or spring to minimize seasonal
variations. Subjects were included if they had no
evidence of previous or current psychiatric illness,
no serious physical illness, no first degree relative
with bipolar disorder, completed suicide or schizo-
phrenia; and no previous exposure to serious trauma.
Volunteers screened positive for pedophilic disorder
were excluded. In total, 39 male volunteers were
included in the study.
Assessments
Both HD patients and healthy volunteers were
assessed using the Mini-International
Neuropsychiatric Interview (MINI 6.0) [24], the
Hypersexual Disorder Screening Inventory
(HDSI) (www.dsm5.org) [25], the Sexual
Compulsivity Scale (SCS) [26], the Hypersexual
Disorder: Current Assessment Scale (HD:CAS)
[3], the Montgomery-Åsberg Depression Rating
Scale Self rating (MADRS-S) [27] and the
Childhood Trauma Questionnaire [28].
Blood sample collection, dexamethasone test and
hormone level analysis
Blood samples were collected in the morning accord-
ing to standard procedures from non-fasted partici-
pants. Analyses of plasma ACTH and Cortisol assays
were performed directly after sampling at the labora-
tory of the Karolinska University Hospital using
a chemiluminescence immunoassay. Low dose dexa-
methasone suppression tests (DST) were performed
in all participants after the baseline plasma samples of
ACTH and Cortisol were collected by administration
of an oral dexamethasone (0.5 mg) at 23.00 h the
same day. The following day, post DST blood samples
were collected at approximately 08.00 h. A plasma
Cortisol level of 138 nmol/l (= 5 g/dl) or higher in
the morning sample after dexamethasone administra-
tion classified as non-suppressed.
Methylation profiling
Genomic DNA was extracted from whole blood of
110 samples using the phenol-chloroform method
[29]. Subsequently, the EZ DNA Methylation –
GoldTM kit (ZymoResearch, USA) was used for
bisulphite conversion. Bisulphite converted DNA
was thereafter hybridized to the Illumina Infinium
Methylation EPIC BeadChip, measuring the
methylation state of over 850 K CpGsites. The
arrays were imaged and analysed using the
Illumina iScan system (Illumina, San Diego, CA,
USA) in which the per cent methylation state of
each CpG-site was quantified.
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Data processing
Preprocessing of the methylation data was per-
formed by background correction, adjustment of
probe type differences, removal of batch effects
and probe exclusion. Subsequently, the global
DNA methylation pattern was adjusted for white
blood cell type heterogeneity. Principal compo-
nent analysis (PCA) was used to identify sample
outliers in the methylation data. Methylation pre-
processing steps were performed using the minfi
[30], watermelon [31], sva [32], ChAMP [33] of
the Bioconductor project and the FactoMineR
[34] package of the CRAN project operable in
R, version 3.3.0. For all other statistical analysis
please see Supplementary material concerning
background correction, adjustment of type I and
type II probes, removal of batch effects and probe
exclusion and correction for white blood cell type
heterogeneity and criteria of sample exclusion.
CpG-site annotation and selection of miRNA-
associated probes
Ninety per cent of the probes on the Illumina
450K Methylation Beadchip are also present on
the Illumina EPIC BeadChip array [35]. The anno-
tation for the EPIC Beadchip provided by Illumina
does not provide information about the informa-
tion about the distance to the TSS. In addition, for
some CpG sites the EPIC annotation may refer to
more than one associated gene. We therefore used
the expanded annotation produced by Price et al.,
originally designed for the 450K array, to define,
for each CpG-site, the distance to the closest tran-
scriptional start site (TSS) and the associated gene
[36]. As such, only CpG-sites present on the
Illumina 450 K methylation beadchip were consid-
ered for further analysis. After the preprocessing
steps outlined above, all CpG-sites annotated to
any known miRNA were included in the study,
resulting in 8,852 miRNA-associated CpG-sites
investigated in the subsequent analysis.
Mirna profiling
RNA extraction
800 ul of thawed EDTA blood samples stored at
80° C were centrifuged for 10 min at 1900 g and
subsequently for 10 min at 16’000 g (4°C). To
extract RNA from 200 µl cell-debris-free super-
natant the miRNAeasy Serum/Plasma Kit
(Qiagen, Hilden, Germany) was used according
to the manufacturer’s instructions.
Reverse transcription and quantitative real-time PCR
To measure miRNA expression, 10 ng of
extracted RNA was reverse transcribed into
cDNA using a TaqMan® miRNA Reverse
Transcription Kit (Applied Biosystems,
Waltham, MA, USA) and specific stem-loop
reverse transcription primers (TaqMan®
MicroRNA Assays for MIR708-5p and
MIR4456; Life Technologies, Carlsbad, CA,
USA). The following running conditions were
applied: 16°C 30 min, 42°C 30 min, 85°C 5
min. RT-PCR was performed using 0.67 µl
cDNA and 9.3 µl RT-PCR Universal Fast
Master Mix (Applied Biosystems) including the
respective miRNA-specific primers. The follow-
ing RT-PCR running conditions were applied:
95°C 20 s (95°C 1 s, 60°C 20 s) x 40; heating
steps 1.9°C/s; cooling steps 1.6°C/s. U6snRNA
was used as an internal control. Analysis was
performed using the ViiA™ 7 Real-Time PCR
System (Applied Biosystems). All measurements
were performed in triplicate.
Sample exclusion considerations
Of the 93 samples included in the epigenome-wide
analysis, two samples did not have enough blood
to perform the RNA extraction. An additional two
samples were switched for two samples that were
not included in the epigenome-wide analysis.
Furthermore, two additional samples were
excluded as these due to methodological reasons
were treated with an adjusted centrifugation pro-
tocol, resulting in six samples being excluded and
a total sample size of 87 individuals included in
the subsequent analysis of expression levels. In the
case of the MIR708 expression levels, 13 of the
remaining subjects exhibited cycle numbers
greater than 35 in two values out of the measured
triplicate and were thus excluded from the analysis
as they were considered unreliable. As a final step,
we performed boxplot diagrams of the expression
levels and excluded four outliers in the MIR4456
data and eight outliers in the case of MIR708.
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After the exclusion steps, 83 subjects for MIR4456
(55 HD and 28 healthy volunteers) and 66 subjects
for MIR708 (45 HD and 21 healthy volunteers)
were included in the subsequent analysis of
expression levels.
Characterization of the validation data set
Data is openly available (E-GEOD-72680) and
were originally published by Kilaru et al. [37].
The study included only African American
patients with the goal of identifying associations
between peripheral blood DNA methylation and
psychiatric symptoms. Blood was collected in
EDTA vacuum tubes prior to extraction. DNA
methylation was assessed in whole blood using
the Illumina 450 K methylation beadchip from
participants of the Grady Trauma Project. For
the purpose of this study, apart from the DNA
methylation data, we made use of the following
phenotypes: age, gender, BMI, the Kreek-McHugh
-Schluger-Kellogg (KMSK) scale [38] measured for
alcohol, and the occurrence of any under treat-
ment depressive disorder, anxiety disorder, bipolar
disorder or post-traumatic stress disorder. We also
made use of the supplied relative proportions of
white blood cell coefficients: B-cells, CD4-T cells,
CD8 T-cells, granulocytes, monocytes and NK-
cells. Please see https://www.ebi.ac.uk/arrayex
press/experiments/E-GEOD-72680/for a list of all
available phenotypes.
Statistical analysis
All statistical analyses were performed using
R statistics, version 3.3.0.
Data analysis
As a proxy variable for ethnicity, subjects were
stratified as being of ‘Scandinavian descent’ if
born in a Scandinavian country (e.g., Denmark,
Finland, Iceland, Norway or Sweden) and with
biological parents born in the same country.
Skewness and kurtosis of the distribution of con-
tinuous variables were evaluated with the Shapiro–
Wilks test. Baseline cortisol levels in both HD
patients and healthy volunteers and HbA1C
(mml/mol) in controls were normally distributed,
whereas the other clinical variables were not. Thus,
the t-test was used to investigate group differences
in baseline cortisol levels and HbA1C (mml/mol)
and the Kruskal–Wallis’ test was used to investi-
gate group differences in the other continuous
variables between HD patients and healthy con-
trols in an unadjusted manner. Chi-squared tests
were used to detect differences in categorical vari-
ables, e.g., gender, depression and DST non-
suppression status.
Adjusting for potential confounders
We considered initially the following variables as
potential confounders in association analysis
between DNA methylation and HD, i.e., depression,
DST non-suppression status, CTQ Total, ACTH
levels after the dexamethasone suppression test
(DST cortisol, DST ACTH), plasma levels of testos-
terone, HBA1C, TSH, TNF-alpha and IL-6. To
avoid overfitting by including too many covariates,
we first investigated each individual covariate
against the phenotype of interest in binary logistic
regression models using the ‘glm’ function in
R. Covariates were incrementally and independently
selected. Only covariates with near significant
between-group differences (p < 0.10) were consid-
ered in the analysis. Using the computed analysis of
variance, we tested whether the addition of
a particular covariate resulted in a better fit to the
model and only included variables with a p-value <
0.05. Age was used as a base covariate for the regres-
sions. The best linear model for hypersexuality
included depression (p = 0.0113), DST outcome (p
= 0.003517), CTQ total (p = 0.0273) and TNF-alpha
(p = 0.01437). Three individuals lacked data for
TNF-alpha and two individuals lacked data for
CTQ total – both were excluded from the analysis
resulting in a total sample size of 88 individuals used
in the subsequent analysis.
DNA methylation association study
The association analyses between DNA methylation
and hypersexuality were tested with linear models
using the ‘limma’ package for R, applying an empiri-
cal Bayes method based on a moderated t-statistic
[39,40]. These linear regressions using limma have
been previously considered fitting for large-scale
methylation studies [39,40]. For statistical analysis,
we transformed the beta values to M-values, which
have been shown to be statistically more robust [41].
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We assumed a linear model where the M values of
each CpG-site were used as a quantitative dependent
trait and the phenotype of interest, e.g., hypersexu-
ality, were used as covariates together with the other
covariates determined to fit to the model. Standard
errors were calculated manually by multiplying the
square root of the posterior values for sigma^2 with
the standard deviation. All analyses were accounted
for multiple testing using the false discovery rate
(FDR) method [42]. As a next step, the R/
Bioconductor package BACON [43] was implemen-
ted to adjust the regression data for estimated bias
and inflation. As a third step, as each gene transcript
may be associated with several CpG-sites, we ana-
lysed the results of the regression analyses to identify
gene transcripts with an abundance of differentially
methylated CpG-sites using binomial tests. P-value
thresholds were set to 0.05 to stratify probes accord-
ing to significant and non-significant methylation
changes. Subsequently, binomial tests were per-
formed in R using the function ‘binom.test’, con-
trasting for each gene the number of nominally
significant CpG-sites to the total number of probes
annotated to each gene transcript not taking the
direction of the methylation change into account.
Binomial test p-values were adjusted for multiple
testing using the FDR-method [42]. Gene transcripts
with an FDR-adjusted binomial test p-value < 0.05
were considered significant.
Post-hoc analysis of main DNA methylation study
Recent studies have indicated that the ComBat func-
tion used for adjustment of batch effects in DNA
methylation data can overcorrect data [44], poten-
tially inflating resulting statistics. To ensure this was
not a source of bias in our main analysis, we
excluded ComBat from the analysis pipeline and
performed the same regression analyses as described
in section 2.5.3. Furthermore, we tested whether the
exclusion of female samples would impact signifi-
cantly on the key results. In a third analysis, all
previously excluded samples were included in the
analysis to investigate the impact of sample exclusion
on downstream results. In a fourth analysis, we
included the above described proxy variable for eth-
nicity as a co-variate to see if this would impact
regression results. Lastly, in a fifth post-hoc analysis,
additional microRNA annotated CpG-sites on the
EPIC array were added to the analysis. For this
final analysis, we made use of the Illumina Manifest
File for the EPIC array. 19627 CpG-sites annotated
to X and Y chromosomes were removed. Thereafter,
an additional 129151 probes with known SNP sites
with a minor allele frequency exceeding 0.05 were
excluded from the analysis. A list of all known
microRNA transcripts for Homo Sapiens was
obtained from miRBase [45]. Remaining CpG-sites
annotated to any known human microRNA were
included in the analysis, resulting in 1465 additional
microRNA-associated CpG-sites. Two hundred and
sixty-eight of these were excluded during the pre-
processing of the methylation data, resulting in 1197
additional CpG-sites added to the DNA methylation
analysis. In total, 10049 (8852 + 1197) CpG-sites
were studied. For all post hoc analyses presented
above, the same analysis pipeline was followed as
that described previously.
Validation cohort analysis
Of the 392 subjects included in the study, we first
excluded 158 subjects lacking KMSK data. Following
this step, we further excluded 127 subjects with
a BMI exceeding 30 kg/m2, resulting in 107 indivi-
duals investigated in the subsequent analysis. Next,
we stratified subjects into ‘alcohol dependent’ or
‘controls’ based on their score for alcohol on the
KMSK. An arbitrary cut-off of 8 was used in order
to achieve sufficient power for the subsequent ana-
lysis. Tang et al. demonstrated that this cut-off
resulted in a sensitivity for alcohol dependence of
98.6%, a specificity of 58.2%, a positive predictive
value of 0.538 and a negative predictive value of
0.988 [38]. To exclude any potential confound from
white blood cell type heterogeneity, which has been
shown to impact the DNAmethylation pattern [40],
we compared the relative proportions of B-cells,
CD4 T-cells, CD8 T-cells, granulocytes and mono-
cytes between subjects stratified as alcohol depen-
dent and controls using unpaired t-tests. We then
considered initially the following variables as poten-
tial confounders on the association analysis between
DNA methylation and alcohol dependence, i.e., age,
gender, BMI, and the occurrence of any under treat-
ment depressive disorder, anxiety disorder, bipolar
disorder or post-traumatic stress disorder. These
parameters were compared between the groups in
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using unpaired t-tests and chi-squared tests. We
thereafter performed binomial logistic regression
models, contrasting disease status (alcohol depen-
dence or control) to candidate CpG-site methylation
levels and adjusting for the co-variates that exhibited
significant between-group differences.
Investigation of the expressional profile of
candidate miRNAs
TaqMan miRNA Reverse Transcription Kit
(Applied Biosystems, Waltham, MA, USA) was
used to measure expression levels miRNAs that
were associated with differentially methylated
CpG-sites identified in the epigenome-wide analy-
sis. Skewness and kurtosis of the distribution of
the expression pattern were evaluated with the
Shapiro–Wilks test. The measured miRNAs were
not normally distributed. The Kruskal–Wallis’ test
was, thus, used to investigate group differences in
the expressional profile between HD patients and
healthy controls. In addition, we performed bino-
mial logistic regressions by contrasting expression
levels between hypersexual patients and healthy
volunteers and adjusting for both continuous vari-
ables, i.e. CTQ total and TNF alpha, as well as the
categorical co-variates, i.e., depression and DST
non-suppression status. Candidate CpG-sites
were further investigated with regard to their asso-
ciation with transcriptional expression of the
respective miRNA. We assumed a linear model,
where the expression levels of each miRNA
(dependent variable) were correlated to M values
of the associated CpG-site (independent variable)
intraindividually, adjusting for a categorical vari-
able of disease state (HD or healthy volunteer) and
an interaction term between methylation and dis-
ease state. As a third step, we also correlated
miRNA expression levels with M values of the
associated CpG-site in the combined Expression
data set, adjusting for a categorical experimental
variable.
Target gene prediction and pathway analysis
We used the online webtool ComIR to identify puta-
tive mRNAs putatively targeted by miRNAs in focus,
a miRNA target prediction tool integrating the
results from several distinguished target prediction
algorithms such as TargetScan, Miranda, PITA and
mirSVR [46]. Genes were considered as putative
targets if the calculated equal abundance score
exceeded 0.9, as performed by Maffioletti et al. [47].
Subsequently, genes identified as putative miRNA
targets were investigated by overrepresentation ana-
lysis of tissue-specific gene expression profiling and
KEGG-defined pathways, using the online web tools
‘DAVID Functional Annotation Bioinformatics
Microarray Analysis’ [48] and ‘ConsensusPathDB-
human’ [49]. For the overrepresentation analysis in
KEGG-defined pathways, we specified a ‘minimum
overlap with input list’ of 15 and a stringent p-value
cut-off of 0.0001. To investigate if there were over-
lapping genes in the identified KEGG-defined path-
ways, we performed a heatmap analysis of the
number of overlapping MIR4456 associated genes
in each pathway using the R package ‘gplots’ [50].
Evolutionary conservation of candidate microRNA:s
BLASTn searches [51] were performed through
the Ensembl (word size = 4 with all other para-
meters default) [52] and NCBI (word size = 16
with all other parameters default) (v. 2.5.0) web-
servers. The relevant hits were retained consider-
ing e-value, sequence identity and appropriate
sequence coverage, i.e., if the seed region of the
mature miRNA was covered. The 10 species with
genomic assemblies include: Homo sapiens
(GRCh38); Pan troglodytes (GSAC 2.1.4); Pan
paniscus (panPan1); Gorilla gorilla gorilla (WTSI
gorGor3.1); Pongo pygmaeus abelii (PPYG2);
Chlorocebus sabaeus (VGC ChlSabeus1.1);
Macaca mulatta (Mmul_8.0.1); Papio anubis
(PapAnu_2.0); Saimiri boliviensis (saiBol1.1); and
Callithrix jacchus (C_jacchus3.2.1). The sequence
regions of interest were downloaded and then
aligned using the Mafft webserver (v 7) [53] with
the L-INS-i method with default settings.
Visualization with nucleotide colouring scheme
and editing of the alignment was performed in
Jalview [54] with further annotation performed
in Adobe Illustrator. The species phylogenetic
tree was created using phyloT [55] and is based
on NCBI taxonomy. The cladogram represents the
evolutionary relationship among the investigated
organisms; the branch lengths are not relative to
evolutionary distances. The gene synteny was
gleaned through the NCBI map view web portal
[56] and through the UCSC genome browser [57].
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Results
Study sample characteristics
In the Discovery cohort, comprising 60 patients
diagnosed with hypersexual disorder (HD) and 33
healthy volunteers, we initially aimed to identify
miRNA genes in proximity of CpG-sites, in which
modifications of the epigenetic profile are associated
with HD. Patients with HD had significantly more
depression (p < 0.05), higher scores on the CTQ
assessment (p < 0.001), higher levels of plasma
ACTH after the DST (p < 0.01) and TNF-alpha (p
< 0.0001), but lower levels of plasma IL-6 (p < 0.001).
In addition, the HD patient group tended to have
more DST non-suppressors as compared to control
group (p = 0.058). There were no significant differ-
ences between groups in age, plasma testosterone
levels, TSH/T4-quota, HbA1C, baseline cortisol,
DST cortisol and baseline ACTH (Table 1)
The Validation cohort comprised 107 subjects,
of which 24 were stratified as alcohol dependent
and 83 as controls based on the results on the
Kreek-McHugh-Schluger-Kellogg (KMSK) score
for alcohol. There were no between-group differ-
ences in cell-type proportions of B-cells, CD4
T-cells, CD8 T-cells, granulocytes, monocytes or
NK-cells as measured by unpaired t-tests (data not
shown). Controls had a significantly higher ratio
of females (p < 0.01) and higher occurrence of
subjects under treatment for anxiety disorders (p
< 0.05). There were no between-group differences
in age, BMI or in the occurrence of any under
treatment depressive disorder, bipolar disorder or
post-traumatic stress disorder (Supplementary
Table 1).
Two CpG-sites linked to MIR708 and MIR4456 are
differentially methylated in subjects with
hypersexual disorder
On the association analysis between DNA methyla-
tion of miRNA coupled CpG-sites and HD, we per-
formed multiple linear regression models of
methylationM-values to HD and adjusted for depres-
sion, DST non-suppression status, CTQ total score
and plasma levels of TNF-alpha. The initial analysis of
the 8,852 individual CpG-sites tested, yielded two
CpG loci that were identified and associated with
the miRNAs MIR708 and MIR4456, respectively,
which were differentially methylated after correction
for multiple testing using the FDR-method (pFDR
<0.05)(Table 2)(Supplementary Figure 1).
Cg18222192 (MIR708) was significantly hypomethy-
lated in subjects with HD, whereas cg01299774
(MIR4456) exhibited a hypermethylation in the
patient group. A Q-Q plot of the moderated t-statistic
further suggested some inflation in the methylation
analysis (Supplementary Figure 2.). Using R/
Table 1. Clinical characteristics of patients with hypersexual disorder and healthy volunteers.
Patients Healthy volunteers Statistics (t-test, Kruskall-Wallis, Chisq.test), p value
N 60 33
Age (years) 39.4 (11.9) 37.4 (11.3) ns
Men:Women, (n (%)) 54 (90.0): 6 (10.0) 33 (100.0): 0 (0.0) ns
Scandinavian descent (n(%))* 43 (71.7) 23 (69.7) ns
Diagnosis depression (n(%)) 9 (0.15) 0 (0.0) 4.83E-02
DST non-suppressors (n(%)) 16 (26.7) 3 (9.1) 5.78E-02
CTQ Total 40.42 (11.89) 32.85 (9.39) 2.22E-04
TSH (mE/L)/T4 (nmol/L) 0.019 (0.0098) 0.027 (0.033) ns
HBA1C (mml/mol) 32.97 (5.70) 32.82 (3.96) ns
Cortisol (nmol/L) 467.85 (132.33) 474.49 (148.32) ns
DST Cortisol (nmol/L) 100.4 (101.3) 62.54 (48.54) ns
ACTH (pmol/L) 6.36 (3.05) 5.82 (2.99) ns
DST ACTH (pmol/L) 2.11 (1.58) 1.26 (0.90) 8.10E-03
Testosteron (nmol/L) 14.02 (5.86) 14.24 (4.37) ns
TNF-alpha (ng/L) 7.26 (1.83) 5.84 (2.41) 4.39E-06
Values are shown as mean (SD) unless otherwise specified. P-values were calculated by means of unpaired t-tests, Kruskall-Wallis’ test or chi-squared
tests, contrasting values for patients with hypersexuality disorder and healthy volunteers. A one-tailed p-value <0.05 was considered significant.
*As a proxy for ethnicity, subjects born in a Scandinavian country (e.g., Denmark, Finland, Iceland, Norway or Sweden) and with biological parents
born in the same country, were stratified as being of ‘Scandinavian descent’.
Abbreviations: CTQ, childhood trauma questionnaire; DST, dexamethasone suppression test; ACTH, ACTH levels after the dexamethasone suppres-
sion test; DST Cortisol, cortisol levels after the dexamethasone suppression test; DST non-suppressors, non-suppression status defined as DST
cortisol levels >138 nmol/l
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Bioconductor package BACON yielded estimated bias
of −0.082 and an estimated inflation of 1.1. Adjusting
for this potential hidden confound yielded consider-
ably less nominally significant CpG-sites (77 com-
pared to 695) and resulted in the CpG sites above
reaching FDR_adjusted p-values of 5.81 E-02. The
BACON adjusted values yielded an estimated infla-
tion of 1.0 and a minimal bias of 0.027. As a next step,
we tested whether any individual miRNA had
a statistically significant abundance of differentially
methylated CpG-sites using binomial tests and
a p-value threshold of 0.05. No individual miRNA
had a statistically significant abundance of differen-
tially methylated CpG-sites after adjustments were
made for multiple testing. The five most significant
miRNA:s were mir-133b, MIR4456, MIR124-1,
MIR100HG and MIRLET7BHG. With 8 out of 33
CpG-sites differentially methylated in HD (p-value
threshold of <0.05), MIR4456 was nominally signifi-
cant in this respect (p < 0.001)(Supplementary
Table 2).
Post-hoc analyses suggest minimal bias from
batch adjustment, inclusion of female samples,
exclusion of outlier samples and ethnicity
Excluding ComBat from the analysis pipeline
resulted in an estimated inflation of 1.3 and
a total of 32 FDR-adjusted significant CpG-sites
(pFDR < 0.05) prior to ‘bacon’-adjustment (com-
pared to two FDR-adjusted significant CpG-sites
when implementing ComBat in the analysis pipe-
line). This represents considerably more inflation
than the ComBat adjusted estimated inflation of
1.1. Likewise, the exclusion of female participants
resulted in MIR4456 associated CpG-site
cg01299774 being the most significant probe
prior to adjustment for bias/inflation (p =
2.053995e-05, pFDR = 0.1094308) albeit not sig-
nificant after FDR-adjustments. Similar results
resulted were obtained when including outlier
samples previously excluded. Furthermore, includ-
ing a categorical variable of ‘Scandinavian descent’
(yes or no) in the methylation analysis did not
significantly alter the results for the MIR4456 asso-
ciated CpG-site in focus, cg01299774 (p = 8.74E-
06, pFDR = 0.049), measured before inflation/bias
adjustment. For this analysis, estimated inflation
was 1.1 and estimated bias −0.085. After adjust-
ment for inflation/bias and FDR-adjustment,
p-value for cg01299774 was 0.098 and the magni-
tude and direction of the methylation change was
the same. Lastly, the inclusion of additional
microRNA-associated CpG-sites annotated to the
EPIC array resulted in MIR708 associated CpG-
site cg18222182 (p = 7.23E-06, pFDR = 0.046) and
MIR4456 associated CpG-site cg01299774
(p = 9.28E-06, pFDR = 0.046) to be significant
after FDR adjustments but prior to inflation/bias
adjustment. Inflation was 1.1 and bias −0.086. No
individual CpG-site remained significant after
Table 2. Hypersexuality associated methylation changes in miRNA-associated CpG sites.
% DNA Methylation (SD)
Gene Transcript Illumina ID Patients Healthy Volunteers logFC ES SE p p (FDR) pBC pBC (FDR)
MIR708 NR_030598 cg18222192 50.1 (3.0) 51.5 (3.7) −0.11 −0.11 2.35E-02 7.04E-06 4.14E-02 1.31E-05 5.81E-02
MIR4456 NR_039661 cg01299774 51.3 (3.4) 48.7 (4.2) 0.12 0.12 2.64E-02 9.36E-06 4.14E-02 8.97E-06 5.81E-02
MIR3141 NR_036094 cg05945665 65.3 (1.6) 66.1 (2.3) −0.09 0.08 2.01E-02 3.75E-05 8.13E-02 6.72E-05 1.17E-01
Mir_584 . cg27571590 73.3 (1.2) 74.0 (1.8) −0.06 0.06 1.53E-02 4.78E-05 8.13E-02 3.66E-04 2.70E-01
MIR4710 NR_039860 cg16761754 38.5 (9.1) 34.0 (12.7) 0.35 −0.09 1.97E-02 4.88E-05 8.13E-02 7.73E-05 1.17E-01
MIR4278 NR_036242 cg08313382 58.5 (1.8) 57.6 (2.7) 0.08 0.09 2.27E-02 5.99E-05 8.13E-02 1.19E-04 1.17E-01
MIR345 NR_029906 cg02540736 53.2 (1.4) 54.1 (2.5) −0.06 −0.07 2.08E-02 6.43E-05 8.13E-02 1.42E-03 4.69E-01
MIR4281 NR_036239 cg20960405 23.6 (1.9) 23.0 (2.8) 0.09 0.09 2.30E-02 9.29E-05 8.28E-02 1.07E-04 1.17E-01
Mir_1302 . cg08241360 59.0 (4.1) 57.3 (6.5) 0.12 −0.03 1.11E-02 9.92E-05 8.28E-02 1.06E-02 6.71E-01
MIR4441 NR_039643 cg20871441 73.5 (1.0) 73.8 (1.0) −0.03 0.04 1.19E-02 1.01E-04 8.28E-02 1.85E-03 4.69E-01
Analysis by multiple linear regression models of methylation M-values to a binary outcome variable of Hypersexuality (Y/N), adjusting for Depression
(Y/N), dexamethasone suppresser (Y/N), CTQ total score and TNF-alpha (ng/L). 8,852 miRNA associated CpG-sites were analysed. Standard errors
were calculated manually by multiplying the square root of the posterior values for sigma^2 with the standard deviation. P-values were corrected
for multiple testing using the false discovery rate (FDR)-method. Correction for inflation and estimated bias was made using the package ‘Bacon’
for R statistics.
Abbreviations: logFC, log fold change of M-values; % DNA Methylation (SD), mean beta value percent DNA methylation (standard deviation); ES,
effect size; SE, standard error; p, p-value; p (FDR), FDR-adjusted p-value; pBC, p-values after bacon adjustment for inflation and bias; pBC (FDR), FDR-
adjusted p-values after bacon adjustment for inflation and bias.
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inflation, bias and FDR-adjustment. The full
results of all the above-presented post-hoc analyses
are presented in Supplementary Materials.
MIR4456 is lower expressed in peripheral blood
of subjects diagnosed with hypersexual disorder
We measured the expression levels of MIR708 and
MIR4456 in blood and compared them between
controls and subjects diagnosed with HD. Due to
hemolysis of the erythrocytes, it was not possible
to separate the plasma from the corpuscular part
of the blood. As such, the miRNA expression levels
are measured on miRNA from plasma and blood
cells. This, however, was the case for all our
samples and should therefore not be a source of
any occurring between-group bias.
As neither of the two miRNAs were normally
distributed, we used the Kruskal–Wallis’ test to
investigate univariate between-group differences
in expression levels. MIR4456 (p < 0.001) was
significantly less expressed in subjects with HD,
but there were no group differences in the expres-
sion of MIR708 (Supplementary Table 3)
(Figure 1). In the following step, we performed
binomial logistic regression analyses, contrasting
miRNA expression levels by disease state (HD or
healthy volunteer) and adjusting for depression,
DST non-suppression status, CTQ total and TNF-
alpha as co-variates. In this analysis, MIR4456
(p < 0.05) remained significantly lower expressed
(Supplementary Table 4).
Expression levels of MIR4456 are significantly
associated with the methylation state of
cg01299774 and the direction of the association
is dependent on disease state
To evaluate to what extent the expression levels of
MIR708 andMIR4456 are associated with the methy-
lation state of the candidate CpG-sites, we performed
multiple linear regressions whereby each miRNA was
correlated to M-values of the associated CpG-site,
adjusting for disease state (hypersexual disorder or
healthy volunteer) and an interaction term between
methylation status and disease state. Cg01299774 was
inversely correlated (p < 0.01)with expression levels of
MIR4456. Specifically, the interaction term composed
of disease state and CpG-site methylation levels had
a positive coefficient (p < 0.01), indicating disease
Figure 1. Boxplot diagram of MIR4456 normalized expression
values in HD and healthy volunteers.
Table 3. Methylation/transcription correlations in HD patients and healthy volunteers of candidate CpG sites and MIR708 and
MIR4456.
MIR708 MIR4456
Coef. Std. Error t value p.val Coef. Std. Error t value p.val
Intercept 0.64 0.08 7.62 1.82E-10 0.79 0.06 13.5 < 2e-16
cg18222192a/cg01299774b 0.63 0.40 1.56 0.13 −0.72 0.25 −2.84 5.76E-03
Disease statec −0.13 0.10 −1.40 0.17 −0.29 0.07 −3.94 1.78E-04
Interaction termd −0.06 0.47 −0.12 0.90 0.90 0.33 2.75 7.37E-03
Multiple linear regressions whereby the expression of each miRNA was correlated to M values of the CpG site intraindividually, adjusting for
a categorical variable of disease state and an interaction term between methylation and disease state. miRNA expression levels were treated as
dependent variable and DNA methylation as independent variable.
acg18222192 in the case of MIR708
bcg01299774 in the case of MIR4456
cA categorical variable of disease state (hypersexuality disorder or healthy volunteer)
dInteraction term between CpG site methylation and a categorical variable of disease state
Abbreviations: coef., regression coefficient; p, p-value
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state-dependent effects on the direction of the associa-
tion between methylation status and expression level.
Cg18222192 was not associated with MIR708 expres-
sion levels (Table 3).
A significant overrepresentation of MIR4456
putative gene targets are preferentially
expressed in brain and involved in major
neuronal molecular mechanisms thought to be
relevant to HD
Using the ComIR analysis software [46], we retrieved
the predicted mRNA targets for MIR4456. 1,142
mRNAs were identified as putative targets for
MIR4456 andwere subsequently investigated by over-
representation analysis of tissue-specific gene expres-
sion and KEGG-defined pathways. There was
a statistically significant overrepresentation of genes
expressed in brain (569 genes, q-value<0.00001),
amygdala (59 genes, q < 0.01), epithelium (201
genes, q < 0.01), teratocarcinoma (50 genes,
q < 0.05) and hippocampus (44 genes, q < 0.05)
(Supplementary Table 5.). Gene set overrepresenta-
tion analysis further revealed an overrepresentation of
genes associated with five KEGG-defined pathways,
including oxytocin signalling pathway (24 genes,
q < 0.01), cAMP signalling pathway (26 genes,
q < 0.01), glutamatergic synapse (18 genes, q < 0.01),
circadian entrainment (16 genes, q < 0.01) and adre-
nergic signaling in cardiomyocytes (21 genes,
q < 0.01)(Table 4). To investigate the occurrence of
overlapping genes between these pathways, we per-
formed a heatmap based on the number of overlap-
ping MIR4456 associated genes in each pathway.
There appeared to be three main clusters of pathways
(Supplementary Figure 3.). Importantly, the oxyto-
cin signalling pathway, which included 24 MIR4456
associated genes, had a maximum overlap of only 13
genes with the other pathways.
MIR4456 appears to be evolutionary conserved
throughout primates
AsmiRNA4456 is identified inmiRBase only inHomo
sapiens, we performed a BLASTn [58] search using the
43-nucleotide stem-loop region to investigate the evo-
lutionary conservation of MIR4646. This resulted in
10 species with relevant hits (Supplementary Figure
4.) with particular emphasis on the conservation in the
seed region. All of the sequences are predicted to form
a hairpin secondary structure. The last common
ancestor of these species appears to be at the advent
of primates. With the conservation in the multiple
sequence alignment and the predicted hairpin second-
ary structures, this might suggest that this region is
conserved from throughout primates.
MIR4456 associated CpG-site cg01299774 is
hypermethylated in alcohol dependence in the
validation cohort
Candidate CpG loci that were differentially methy-
lated in HD and annotated to miRNA that were
differentially expressed in HD, were further inves-
tigated for an association with alcohol dependence
in the validation cohort. We performed binomial
logistic regression models of disease state (alcohol
dependent or control) to CpG-site methylation
levels and adjusting for the co-variates with sig-
nificant between-group differences, i.e., gender
and occurrence of any under treatment anxiety
disorder. Cg01299774, the only investigated CpG-
site, was significantly hypermethylated in alcohol
dependence (p = 0.0261)(Supplementary Table
6.)(Supplementary Figure 5.).
Table 4. Gene set overrepresentation analysis of MIR4456 putative binding targets – KEGG defined pathways.
KEGG Pathway (Homo sapiens) Set size Count % p-value q-value source
Oxytocin signaling pathway 159 24 15.2% 7.29E-06 1.82E-04 KEGG
cAMP signaling pathway 200 26 13.0% 5.12E-05 4.14E-04 KEGG
Glutamatergic synapse 114 18 15.8% 5.92E-05 4.14E-04 KEGG
Circadian entrainment 96 16 16.7% 7.76E-05 4.14E-04 KEGG
Adrenergic signaling in cardiomyocytes 149 21 14.1% 8.28E-05 4.14E-04 KEGG
The online web tool ComIR’ was used to computationally predict putative gene targets of MIR4456. Using the online web tool ‘ConsensusPathDB-
human’, 1142 identified genes were investigated to see if there was a statistically significant abundance of genes involved in specific KEGG-defined
pathways. We specified a ‘minimum overlap with input list’ of 15 genes and a stringent p-value cut-off of 0.0001.
Abbreviations: Count, number of candidate genes in a particular pathway; %, percentage of candidate genes in a particular pathway
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Discussion
In a DNA methylation association analysis in per-
ipheral blood, we identify distinct CpG-sites asso-
ciated with MIR708 and MIR4456 that are
significantly differentially methylated in HD
patients. Additionally, we demonstrate that hsa-
miR-4456 associated methylation locus cg01299774
is differentially methylated in alcohol dependence,
suggesting that it may be primarily associated with
the addictive component observed in HD. We
demonstrate that MIR4456 is considerably lower
expressed in blood of HD patients using both uni-
variate and multivariate analyses. Importantly, the
differential expression status of MIR4456 is asso-
ciated with epigenetic shifts in the identified methy-
lation locus. Interestingly, this miRNA putatively
targets several genes that are preferentially expressed
in brain, amygdala and hippocampus and are
involved in major neuronal molecular mechanisms
thought to be relevant for HD, e.g., the oxytocin
signalling pathway. Our findings suggest a role of
MIR4456 in the pathogenesis of HD, whichmight be
regulated by methylation shifts in the identified
methylation locus.
To our knowledge, this is the first published study
investigating associations between both DNA
methylation and miRNA expression levels in HD.
By choosing a methylome-wide study approach
using the Illumina EPIC methylation array, it was
possible to comprehensively investigate 8,852
miRNA-associated CpG-sites with regard to changes
in methylation patterns in a hypothesis-free and
unbiased manner. Specifically, MIR4456 had both
a genome-wide significant methylation locus and
a statistically significant abundance of nominally
significant probes, providing evidence that
MIR4456 associated methylation alterations occur
in HD subjects. To our knowledge, no previous
paper described the importance of MIR4456 in
a context of psychopathologies. We identify that
this miRNA is evolutionarily conserved with regard
to primary sequence composition and predicted
hairpin secondary structures from the advent of
primates. In addition, we provide evidence that puta-
tive mRNA targets of MIR4456 are preferentially
expressed in amygdala and hippocampus, two
brain regions suggested by Kühn et al. to be impli-
cated in the pathophysiology of HD [5].
The involvement of the oxytocin signalling
pathway identified in this study appears to be
significantly implicated in many of the character-
istics defining HD as proposed by Kafka et al. [1],
such as sexual desire dysregulation, compulsivity,
impulsivity and (sexual) addiction. Mainly pro-
duced by the paraventricular nucleus of the
hypothalamus and released by the posterior pitui-
tary, oxytocin plays an important role in social
bonding and sexual reproduction in both males
and females [59]. Murphy et al. described elevated
levels during sexual arousal [60]. Burri et al. found
that intranasal oxytocin application in men
resulted in an increase in epinephrine plasma
levels during sexual activity and an altered percep-
tion of arousal [61]. Additionally, oxytocin has
been proposed to inhibit the activity of the
hypothalamic-pituitary-adrenal (HPA) axis during
stress. Jurek et al. observed that oxytocin receptor-
mediated intracellular mechanisms postpone the
transcription of corticotropin-releasing factor
(Crf) in the paraventricular nucleus, a gene
strongly associated with the stress response [62].
Alterations in the oxytocin signalling pathway
could explain findings by Chatzittofis et al., who
observed HPA axis dysregulation in men with
hypersexual disorder [3]. Furthermore, studies
indicate that oxytocin may be involved in the
pathophysiology of obsessive-compulsive disorder
[63]. The interaction of oxytocin with the dopa-
mine system, the HPA-axis and the immune sys-
tem led to the postulation that individual
differences in oxytocin levels are impacting addic-
tion vulnerability [64]. While oxytocin has been
previously associated with the regulation of social
and aggressive behaviour, Johansson et al. further
demonstrated that genetic variation in the oxyto-
cin receptor gene (OXTR) impacted on the ten-
dency to react to situations with elevated levels of
anger under the influence of alcohol [65]. Lastly,
Brüne et al. concluded that genetic variation in
OXTR may contribute to explaining the pathophy-
siology of borderline personality disorder [66],
a personality pathology characterized by severe
impulsivity dysregulation [66].
MIR4456 may have an additional regulatory func-
tion in HD that was not revealed in the current
study. In line with our findings, previous studies
have reported associations of aberrant male sexual
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behaviour and genes involved in glutamatergic sys-
tem in depressed individuals [67]. Furthermore,
a potential role of the 3ʹ-5ʹ-cyclic adenosine mono
phosphate (cAMP) levels in sexual receptivity was
shown in female rats, by modulating the phospho-
protein-32 and leading to alterations of progestin
receptors [68]. Interestingly, cAMP also regulates
molecules associated with axon guidance [69], such
as the B3gnt1 gene, which was associated with
impaired sexual behaviour in male mice [70].
Our study has several limitations. First, while the
Illumina EPIC methylation array has been proven to
be highly reproducible and reliable [35], it would be
valuable to confirm the differential methylation sta-
tus of the MIR4456 associated CpG locus in an
independent cohort of HD patients. Second, in the
expression profiling of MIR4456 andMIR708, it was
not possible to separate the plasma from the blood
samples due to hemolysis of the erythrocytes. As
such, the measured miRNA expression levels are
based on miRNAs from both plasma and lysed
blood cells. This, however, was the case for all our
samples and should therefore not be a source of
between-group bias. Third, putative mRNA targets
of MIR4456 were identified by computer algorithms.
Thus, further in vivo studies are needed to confirm
the predicted MIR4456 targets to further assure the
hypotheses drawn with regard to a MIR4456 asso-
ciated regulation of oxytocin signalling. Fourth,
while MIR4456 is shown to be differentially
expressed in whole blood of HD patients, we do
not know to what extent this finding reflects expres-
sion modifications occurring in brain. Fifth, we took
the most important confounders available, such as
depression, DST non-suppression status, CTQ total
score and plasma levels of TNF-alpha, into consid-
eration, in association analyses between methylation
and hypersexuality. The patient population was as
homogenous as found reasonable, excluding subjects
with psychotic illness, alcohol or drug abuse, other
psychiatric disease requiring immediate treatment
and other severe physical illness. However, other
potential confounding factors, e.g., dietary patterns,
ethnicity or prandial states may be able to induce
changes in methylation patterns as well [40].
Furthermore, as the mean difference in per cent
DNA methylation between HD patients and healthy
volunteers was only ~2.6% it can be called into
question what impact such small methylation
changes would have on physiology. There is, how-
ever, now a growing body of literature on specific
genes, suggesting wide ranging transcriptional and
translational consequences of subtle methylation
changes (1–5%), especially in complex multifactorial
conditions like depression or schizophrenia [71].
Lastly, due to improved annotation, our analysis
was restricted to CpG sites on the Illumina 450K
array. As such, this could be considered
a limitation as we did not make use of the full
potential of the EPIC array.
In conclusion, MIR4456 has significantly lower
expression in HD. Our study provides evidence that
DNA methylation at the cg01299774 locus is asso-
ciated with the expression of MIR4456. This miRNA
putatively targets genes preferentially expressed in
brain tissue and involved in major neuronal molecu-
lar mechanisms thought to be relevant to the patho-
genesis of HD. Our findings from the investigation of
shifts in the epigenome contributes to further eluci-
dating the biological mechanisms behind the patho-
physiology of HD with special emphasis on MIR4456
and its role in oxytocin regulation. Further studies
are needed to confirm and further elucidate the exact
interplay between MIR4456 and the oxytocin signal-
ling pathway in HD.
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